Minimal Residual Disease following Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1 SUPPL, 2011, Pages

  Kröger, Nicolaus ^a   Miyamura, Koichi ^b   Bishop, Michael R ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allogeneic; DLI; Graft versus tumor; Minimal residual disease; Relapse

Indexed keywords

5,6 DIHYDROAZACITIDINE; ALEMTUZUMAB; BORTEZOMIB; DEXAMETHASONE; IMATINIB; LENALIDOMIDE; RITUXIMAB; THALIDOMIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; GRAFT VERSUS HOST REACTION; HUMAN; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PHILADELPHIA CHROMOSOME POSITIVE CELL; TREATMENT OUTCOME;

EID: 78650639463     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.10.031     Document Type: Article

References (44)

1. Pavletic S.Z., Kumar S., Mohty M., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant 2010, 16:871-890.
2. Sawyers C.L., Timson L., Kawasaki E.S., Clark S.S., Witte O.N., Champlin R. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci U S A 1990, 87:563-567.
3. Pérez-Simón J.A., Caballero D., Diez-Campelo M., et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002, 16:1423-1431.
4. Shimoni A., Nagler A. Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning. Acta Haematol 2004, 112:93-104.
5. Elorza I., Palacio C., Dapena J.L., Gallur L., de Toledo J.S., de Heredia C.D. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica 2010, 95:936-941.
6. Moreno C., Villamor N., Colomer D., et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006, 107:4563-4569.
7. Bacher U., Zander A.R., Haferlach T., Schnittger S., Fehse B., Kröger N. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant 2008, 42:145-157.
8. Bader P., Kreyenberg H., Henze G.H., et al. ALL-REZ BFM Study Group. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009, 27:377-384.
9. Gratwohl A., Brand R., Frassoni F., et al. Acute and Chronic Leukemia Working Parties; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005, 36:757-769.
10. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
11. Welniak L.A., Blazar B.R., Murphy W.J. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007, 25:139-170.
12. Raanani P., Dazzi F., Sohal J., et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 1997, 99:945-950.
13. Bader P., Klingebiel T., Schaudt A., et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999, 13:2079-2086.
14. Kröger N., Bacher U., Bader P., et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part I: methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 2010, 16:1187-1211.
15. Kröger N., Zagrivnaja M., Schwartz S., et al. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly-sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. Exp Hematol 2006, 34:688-694.
16. Radich J.P., Gehly G., Gooley T., et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995, 85:2632-2638.
17. Lin F., van Rhee F., Goldman J.M., et al. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996, 87:4473-4478.
18. Alchalby H., Badbaran A., Zabelina T., et al. Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010 May 20, [Epub ahead of print].
19. Kröger N., Bacher U., Bader P., et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part II: chronic leukemias, myeloproliferative neoplasms and lymphoid malignancies. Biol Blood Marrow Transplant 2010, 16:1325-1346.
20. Corradini P., Cavo M., Lokhorst H., et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003, 102:1927-1929.
21. Miyamura K., Barrett A.J., Kodera Y., Saito H. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results. Bone Marrow Transplant 1994, 14:201-209.
22. Miyamura K., Morishima Y., Tanimoto M., et al. Prediction of clinical relapse after bone-marrow transplantation by PCR for Philadelphia-positive acute lymphoblastic leukaemia. Lancet 1990, 336:890.
23. Miyamura K., Tahara T., Tanimoto M., et al. Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients. Blood 1993, 81:1089-1093.
24. Miyamura K., Tanimoto M., Morishima Y., et al. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood 1992, 79:1366-1370.
25. Akatsuka Y., Morishima Y., Kuzushima K., Kodera Y., Takahashi T. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions. Cancer Sci 2007, 98:1139-1146.
26. Warren EH, Fujii N, Akatsuka Y, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood;115:3869-3878.
27. Zhou Q., Bucher C., Munger M.E., et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 2009, 114:3793-3802.
28. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
29. Nishiwaki S., Miyamura K., Kato C., et al. Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. Anticancer Res 2010, 30:2415-2418.
30. Ottmann O.G., Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematology Am Soc Hematol Educ Program 2009, 371-381.
31. Ladetto M., Pagliano G., Ferrero S., et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010, 28:2077-2084.
32. Koreth J., Alyea E.P., Murphy W.J., Welniak L.A. Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review. Biol Blood Marrow Transplant 2009, 15:1502-1512.
33. Minnema M.C., van der Veer M.S., Aarts T., Emmelot M., Mutis T., Lokhorst H.M. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009, 23:605-607.
34. Lokhorst H., Einsele H., Vesole D., et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010 Sep 20, International Myeloma Working Group, [Epub ahead of print].
35. Jabbour E., Giralt S., Kantarjian H., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899-1905.
36. Sánchez-Abarca L.I., Gutierrez-Cosio S., Santamaría C., et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010, 115:107-121.
37. Raptis A., Agha M., Shah M. Salvage of donor graft with decitabine and maintenance post allogeneic stem cell transplantation in myelodysplastic/myeloproliferative disease: a case report. Clin Leuk 2009, 3:22-23.
38. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004, 32:28-35.
39. Kennedy-Nasser A.A., Bollard C.M., Myers G.D., et al. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant 2008, 14:1245-1252.
40. Bishop M.R., Alyea E.P., Cairo M.S., et al. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010, 16:563-564.
41. Miller J.S., Warren E.H., van den Brink M.R., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: graft-versus-tumor/leukemia reaction. Biol Blood Marrow Transplant 2010, 16:565-586.
42. Cairo M.S., Jordan C.T., Maley C.C., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: state of the science. Biol Blood Marrow Transplant 2010, 16:709-728.
43. Alyea E.P., DeAngelo D.J., Moldrem J., et al. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the Committee on Prevention of Relapse following Allogeneic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant 2010, 16:1037-1069.
44. Porter D.L., Alyea E.P., Antin J.H., et al. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010, 16:1467-1503.